Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.30 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.30 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3319881 | 1.00 | CES2 (0.33) | CES2CES1SPHK1USP2HTT | |
| SCHEMBL3320341 | 0.75 | KDM4E (0.34) | CES2CES1 | |
| SCHEMBL5202044 | 0.75 | KDM4E (0.34) | CES2CES1 | |
| SCHEMBL4791083 | 0.74 | DNM1 (0.42) | HTTLPAR3LPAR2LPAR1 | |
| SCHEMBL5207642 | 0.74 | DNM1 (0.37) | CES2CES1 | |
| SCHEMBL5204920 | 0.74 | DNM1 (0.37) | CES2CES1 | |
| SCHEMBL3313375 | 0.74 | DNM1 (0.37) | CES2CES1 | |
| SCHEMBL29034461 | 0.72 | DNM1 (0.46) | HTTLPAR3LPAR2LPAR1 | |
| SCHEMBL6679948 | 0.72 | DNM1 (0.46) | HTTLPAR3LPAR2LPAR1 | |
| SCHEMBL5207968 | 0.69 | PPARG (0.41) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1115693-B9 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO CO (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1115693-B1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO CO (US) | 2007-05-02 | — | — | EP | disclosed |
| US-6765023-B2 | SUCH AS 3-((3-(3-TRIFLUOROMETHOXYPHENOXY)PHENYL)((3-(1,1,2,2-TETRAFLUOROETHOXY) -PHENYL)METHYL) AMINO)-1,1,1-TRIFLUORO-2-PROPANOL FOR TREATING CARDIOVASCULAR DISORDERS AND DYSLIPIDEMIA | PFIZER, INC. | 2004-07-20 | — | — | US | disclosed |
| US-6710089-B2 | ATHEROSCLEROSIS; CARDIOVASCULAR DISORDERS; ANTICHOLESTEROL AGENTS | PHARMACIA CORPORATION | 2004-03-23 | — | — | US | disclosed |
| US-6699898-B2 | METHOD OF TREATING CORONARY ARTERY DISEASE OR OTHER CETP-MEDIATED DISORDERS IN A SUBJECT BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND OF ONE OF CLAIMS | PHARMACIA CORPORATION GLOBAL PATENT DEPARTMENT | 2004-03-02 | — | — | US | disclosed |
| US-6696435-B2 | FOR TREATING ATHEROSCLEROSIS, OTHER CORONARY ARTERY DISEASES; 3-((3-(3-TRIFLUOROMETHOXYPHENOXY)PHENYL)((3-(1,1,2,2-TETRAFLUOROETHOXY) -PHENYL)METHYL) AMINO)-1,1,1-TRIFLUORO-2-PROPANOL FOR EXAMPLE | PHARMACIA CORPORATION | 2004-02-24 | — | — | US | disclosed |
| US-6696472-B2 | TREATING ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES | PHARMACIA CORPORATION | 2004-02-24 | — | — | US | disclosed |
| US-6683099-B2 | FOR THERAPY OF ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES | PHARMACIA CORPORATION | 2004-01-27 | — | — | US | disclosed |
| US-6677380-B2 | ANTILIPEMIC AGENTS SUCH AS 3(3-(4-CHLORO-3-ETHYL-PHENOXY)-PHENYL)((3-(1,1,2,2 -TETRAFLUOROETHOXY)PHENYL)METHYL))AMINO)-1,1,1-TRIFLURO-2-PROPANTHIOL, USED FOR PROPHLAXIS OF CARDIOVASCULAR DISORDERS AND ATHEROSCLEROSIS | PHARMACIA CORPORATION | 2004-01-13 | — | — | US | disclosed |
| US-6677375-B2 | TREATING CARDIOVASCULAR DISEASES | PHARMACIA CORPORATION | 2004-01-13 | — | — | US | disclosed |
| US-6476075-B1 | Use of substituted N, N-bis-benzyl aminoalcohol compounds inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2002-11-05 | — | — | US | disclosed |
| US-6476057-B1 | ANTICHOLESTEROL AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. | 2002-11-05 | — | — | US | disclosed |
| US-6462092-B1 | SUCH AS 3-((3-FLUOROPHENYL)-((3-(TRIFLUOROMETHYL)PHENYL)-METHYL)AMINO)-1,1,1 -TRIFLUORO-2-PROPANOL; CARDIOVASCULAR DISEASE, I.E. ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES | G.D. SEARLE & CO. | 2002-10-08 | — | — | US | disclosed |
| US-6458803-B1 | COMPOSITIONS AND METHODS FOR TREATING ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES. PREFERRED TERTIARY-HETEROALKYLAMINE COMPOUNDS ARE SUBSTITUTED N-PHENYL-N-HETEROARALKYL AMINOALCOHOLS. A PREFERRED SPECIFIC | G.D. SEARLE & CO. | 2002-10-01 | — | — | US | disclosed |
| US-6458849-B1 | METHOD OF TREATING OR PREVENTING A CEIP-MEDIATED DISORDER IN A SUBJECT BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND FOR STROKES | G.D. SEARLE & CO. | 2002-10-01 | — | — | US | disclosed |
| US-6458852-B1 | A METHOD OF TREATING OR PREVENTING A CETP-MEDIATED DISORDER IN A SUBJECT BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. | 2002-10-01 | — | — | US | disclosed |
| US-6455519-B1 | TREATING ATHEROSCLEROSIS AND CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. | 2002-09-24 | — | — | US | disclosed |
| US-6451830-B1 | Use of substituted N,N-disubstituted non-fused heterocyclo amino compounds for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2002-09-17 | — | — | US | disclosed |
| US-6451823-B1 | Use of substituted N-phenoxy-N-phenyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2002-09-17 | — | — | US | disclosed |
| US-6448295-B1 | TREATING CARDIOVASCULAR DISEASE; ATHEROSCLEROSIS, DYSLIPIDEMA HYPERCHOLESTEROLAEMIA; DECREASING CONCENTRATIONS OF LOW DENSITY LIPOPROTEIN AND RAISING LEVEL OF HIGH DENSITY LIPOPROTEIN | G.D. SEARLE & CO. | 2002-09-10 | — | — | US | disclosed |